Home About Us Pipeline News Investors Contacts Careers


News

Recent Press Releases Archives

Recent Press Releases

必威体育首页下载平台

必威体育首页代理网址 - Puma Biotechnology Reports Second Quarter 2019 Financial Results
Read

必威体育首页娱乐在线 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

必威体育首页信誉 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

必威体育首页娱乐平台 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read

必威体育首页信誉 - Puma Biotechnologys Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NERLYNX (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive, HER2-Positive Early Stage Breast Cancer
Read

必威体育首页代理网址 - Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019
Read

必威体育首页检测检测 - Puma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Read

必威体育首页首页ios - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

必威体育首页官网 - Puma Biotechnology Presents Results from Phase III NALA Trial of Neratinib in Patients with HER2 Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting
Read

必威体育首页信誉 - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting
Read

必威体育首页代理网址 - Puma Biotechnology to Present at Jefferies 2019 Global Healthcare Conference
Read

必威体育首页下载线路 - Puma Biotechnology Reports First Quarter 2019 Financial Results
Read

必威体育首页官网二维码 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019
Read

必威体育首页检测检测 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read

必威体育首页下载线路 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

必威体育首页娱乐平台 - Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations
Read

必威体育首页官网二维码 - Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX (neratinib) in Europe
Read

必威体育首页首页安卓 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019
Read

必威体育首页检测检测 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting - Oral Plenary Presentation Receives SGO Presidential Award
Read

必威体育首页二维码官网 - Puma Biotechnologys Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

必威体育首页二维码官网 - Puma Biotechnology to Present at Cowens Annual Health Care Conference
Read

必威体育首页代理网址 - Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results
Read

必威体育首页下载线路 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

必威体育首页下载线路 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results
Read

必威体育首页下载线路 - Puma Biotechnology Announces Litigation Victory with Jurys Decision
Read

必威体育首页娱乐平台 - Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX (neratinib) in Canada
Read

必威体育首页在线平台 - Puma Biotechnology to Present at J. P. Morgan Healthcare Conference
Read

必威体育首页娱乐平台 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read




Corporate Fact Sheet

必威体育首页注册app

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax